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OBJECTIVES: To compare informal caregiver burden of caregivers providing care to 
elderly individuals with and without Parkinson’s disease (PD) and estimate costs 
associated with providing informal care to elderly individuals with and without 
PD. METHODS: A retrospective cross-sectional study was conducted using National 
Alliance for Caregiving, American Association of Retired Persons (NAC/AARP) survey 
(2004, 2009). Adults (age ≥ 18 years) with no formal caregiving training, who provided 
help with at least one activity of daily living or instrumental activity of daily living 
were classified as informal caregivers. The care-recipients were elderly (age ≥ 65 
years) individuals with and without PD. Caregiver burden was measured (scale of 
1[low] - 5[high]) based on three questions on physical strain, emotional stress and 
financial hardship on the caregivers. Costs associated with informal care were esti-
mated by multiplying number of informal caregiver hours per week by the median 
wage ($10.10/hour) of a household aide (2013 US$). Mean differences in caregiver 
burden and costs were evaluated with t-tests. Multiple linear regressions were con-
ducted to compare caregiving burden and costs among individuals with and without 
PD. RESULTS: The mean caregiver burden was similar among caregivers of individu-
als with and without PD (2.25 vs. 2.21). Although not statistically significant, the 
average number of caregiving hours per week for care-recipients with PD was higher 
(27.51 hours, 95% CI: 14.4- 41.2) than those without PD (19.73 hours, 95% CI: 18.3- 
21.2). The average costs of informal caregiving for care-recipients with and without 
PD were approximately $14,448 and $11,355 respectively. Multivariate analyses did 
not show significant differences in caregiver burden and costs. CONCLUSIONS: No 
significant differences in caregiver burden and costs were observed among caregiv-
ers of care-recipients with and without PD. Appropriate interventions are needed 
to reduce number of hours of informal caregiving, which may lead to decrease in 
overall informal caregiver burden.
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OBJECTIVES: Approximately 1/3 of patients with partial-onset seizures (POS) are 
drug resistant and frequently require adjunctive treatment (Brodie 2012). Although 
adjunctively-treated patients are identified in claims data by the concurrent admin-
istration of two or more AEDs, the minimum AED co-administration period has not 
been established. In order to avoid confounding in claims data analyses, the titration 
time to maintenance dose of AEDs used in adjunctive therapy needs to be carefully 
weighed in the classification of adjunctively-treated patients. This study sought 
to identify the impact of different co-administration periods on the proportion of 
patients identified as receiving adjunctive therapy within claims data. METHODS: 
This retrospective study used the HCMS employee database of commercially insured 
subjects. Subjects with POS [ICD9-CM= 345.4x,345.5x] between Jan-2001 and Jun-30-
2014 were identified from the employee’s spouses and assigned an index date based 
on their initial AED use. Subjects were required to have > 365 days of continuous 
eligibility following their index date. Patients were classified as having adjunctive 
therapy on the basis of having at least 30, 45, 60, or 90 days of concomitant AED 
use in the year following the index date. RESULTS: 350 eligible subjects married 
to employees were identified (69.5% female, 44.2 years old). The average time from 
their first POS diagnosis was 17.8 days for those initiating monotherapy, and 56.6 
days for those initiating adjunctive therapy; with progression from monotherapy 
to adjunctive therapy averaging 41.4 days. Percent classified receiving adjunctive 
therapy at 30, 45, 60, and 90-days were 41.7%, 39.1%, 38.3% and 34.9%, respec-
tively. CONCLUSIONS: Using a 90-day co-administration period, approximately 1 
in 3 POS subjects were classified as using adjunctive therapy. Researchers may find 
this consideration of different overlap periods useful for studies of AEDs requiring 
short vs. long titration periods.
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OBJECTIVES: To describe the changing landscape of disease modifying therapy 
(DMT) prescribing among treatment-naïve patients diagnosed with multiple scle-
rosis (MS) since the recent introduction of oral options. METHODS: Adult (≥ 18 
years) patients with a diagnosis of MS (ICD-9-CM 340) and ≥ 2 claims for an oral 
(fingolimod, teriflunomide, dimethyl fumarate) or non-oral (interferon beta-1a, 
interferon beta-1b, glatiramer acetate, natalizumab) DMT between March 29, 
2013 and February 1, 2014 (first prescription= index date) were identified in the 
Truven Health MarketScan® databases. Patients had ≥ 15 months of continuous 
enrollment (12 months pre- and 3 months post-index) with no DMT pre-index. 
Demographic and clinical characteristics were measured and compared at index 
and in the 12 month baseline period, respectively. RESULTS: A total of 3,221 
patients (mean age 46.5 years [SD= 11.6]; 75.2% female) met all study criteria. 
Approximately half (49.3%) of patients were prescribed an oral DMT. The most 
commonly prescribed DMT was dimethyl fumarate (38.2%), followed by glatiramer 
acetate (23.1%), natalizumab (8.9%) and intra-muscular interferon beta-1a (8.4%). 
Patients initiating treatment with an oral DMT were older (47.5 years [SD= 10.9] 
vs. 45.5 years [SD= 11.6]) and a higher proportion were prescribed symptomatic 
medications including antidepressants (39.1% vs. 32.2%), muscle relaxants (33.5% 
abstraction and who experienced ≥ 1 cluster within the 12 months prior to the 
abstraction were eligible. Demographics, comorbidities, and seizure-related medical 
information including treatments, rescue medication, and resource utilization over 
a 12-month period were abstracted by the neurologist using a web-based form. Costs 
were estimated from the literature and converted to 2013 US dollars. RESULTS: 
543 patient charts were collected; the mean patient age was 41 years and 58.7% 
were male. In this patient sample, 363 patients were utilizers of rescue medication 
(defined as those who consistently used rescue medication for every seizure cluster) 
and 180 were under-utilizers (not prescribed or failed to use rescue medication for at 
least 1 seizure cluster). Utilizers and under-utilizers experienced on average 2.4 and 
3.1 seizure clusters, respectively. Compared to utilizers, under-utilizers were more 
likely to progress to status epilepticus (25.0% vs. 15.4%, p< 0.01), visit an emergency 
department (56.7% vs. 45.2%, p= 0.012), and require hospitalization (41.1% vs. 25.6%, 
p< 0.01). Healthcare costs were significantly higher for under-utilizers than for uti-
lizers ($21,790 vs. $13,265, p= 0.038). CONCLUSIONS: In this study of adult patients 
with seizure clusters, under-utilizers of rescue medication had significantly higher 
seizure-related healthcare resource use and costs compared to utilizers of rescue 
medications. Supported by Acorda Therapeutics Inc.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic, progressive disease. Mobility and 
walking impairment affect up to 90% of MS patients (Hemmett et al 2004). In clinical 
trials, walking impairment is often measured by walking speed (WS). The impact of 
walking impairment on direct and indirect healthcare resource utilisation (HCRU) 
and support resources, such as walking aids and home/workplace modifications, 
provides important information on burden of MS-related symptoms for health-
care decision makers. This analysis sought to investigate association between WS, 
measured by timed 25 foot walk test (T25FW), and direct HCRU, walking aid use and 
modifications to daily living at home and work. METHODS: Data were obtained 
from a cross-sectional 2014 study of 474 neurologists in France, Germany, Italy, 
Spain, UK and US. Neurologists completed 10-15 prospective records for consulting 
MS patients. Of the total 5538 MS patients, 737 had a T25FW score, and of these, 
320 returned a self-completion form reporting on the utilization of support ser-
vices. Mean age was 43.45 years. Mean time since diagnosis was 6.73 years. Logistic, 
Ordered Logistic, Negative Binomial and Probit (with sample selection) regressions 
assessed the relationship between WS and physician-reported data on direct 
patient HCRU and patient-reported data on walking aids and home and workplace 
modifications. Covariates were age, sex, body mass index, time since MS diagnosis 
and relevant concomitant conditions RESULTS: Reduced WS was associated with 
increased level of non-professional and professional caregiver need (p< 0.001), an 
increase in consultations with physiotherapists (p= 0.001) and urologists (p= 0.033) 
in the last 12 months, and increased visits to ER in the same timeframe (p= 0.010). 
Reduced WS was also associated with increased need for walking aids (p< 0.001) and 
home (p< 0.001), and workplace modification (p= 0.006). CONCLUSIONS: Reduction 
in WS is associated with increased HCRU and additional support requirements. 
Therapies that improve patients’ WS may be beneficial to reduce economic burden 
associated with reduced WS.
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BACKGROUND: While prior studies have supported clinical and health-related 
quality-of-life benefits of dalfampridine extended release tablets (D-ER; fampri-
dine outside the US, 10 mg twice daily) in persons with multiple sclerosis (MS), 
there are limited real-world data on economic benefits as measured by health-
care resource utilization. OBJECTIVES: To evaluate healthcare resource utiliza-
tion associated with D-ER. METHODS: Using the HealthCore Integrated Research 
DatabaseSMof administrative claims from a large, geographically diverse, US 
population between 1/1/2009 and 2/28/2013, resource utilization was compared 
between patients with MS treated with D-ER versus not. Patients aged ≥ 18 years; 
with ≥ 2 pre-index MS-related medical or pharmacy claims and ≥ 12 months each 
of pre-index and post-index continuous enrollment; and without prior claims for 
D-ER and alternate gait-impairing etiologies were included. The D-ER cohort had 
≥ 1 D-ER claim from 1/1/2010 to 2/29/2012, while the cohort not receiving D-ER had 
≥ 1 medical claim(s) with a walking-attributable code (ICD-9-CM 781.2, 719.7, 781.0, 
781.3) and no D-ER use; in both cohorts the index date was the earliest relevant 
claim. The cohorts were propensity-score matched on baseline demographics, 
comorbidities, and MS-related resource utilization. Walking-attributable hospi-
talizations, emergency department (ED), neurologist office, and physical or occu-
pational therapy visits were compared from baseline to 1-year follow-up between 
cohorts. RESULTS: 958 propensity-score–matched patients (479 per cohort) were 
identified. Walking-attributable outcomes for total hospitalizations, measured as 
the change (follow-up minus baseline) between those on and not on D-ER, were 8 
and 31, respectively. Similarly, changes between cohorts in ED visits were –3 and 6; 
neurologist office visits, –52 and 354; and physical or occupational therapy visits, 
90 and 1474 respectively. There was a significant difference in utilization changes 
from baseline to follow-up between cohorts (P< .05). CONCLUSIONS: Results dem-
onstrated favorable walking-attributable resource utilization outcomes associated 
with D-ER treatment.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A291
as the use of ≥ 2 AEDs with an overlap of at least 14 days following index date. 
Treatment patterns consisting of additions, switches, and discontinuations in 
the 1-year follow up period were assessed for patients on mono vs. combina-
tion therapy. Logistic regression was used to evaluate the association of mono 
vs. combination therapy and types of treatment patterns while controlling for 
demographics, chronic disease score (CDS), mental comorbidities, and type of 
epilepsy. SAS 9.3 was used for statistical analyses. RESULTS: Patients with epilepsy 
(n= 4,163) had a mean age of 37.8±13.3 years, were primarily female (57.8%), White 
(41.5%), on monotherapy (87.6%), with a mean CDS of 1.2±3.0. Of the patients on 
monotherapy (n= 3,647) 4.3% added, 14.2% switched, and 46.7% discontinued the 
index AED. Of the patients on combination therapy (n= 516), 5.6% added, 7.9% 
switched, and 38.6% discontinued at least one of the index AEDs. Logistic regres-
sion showed that the likelihood of change in treatment patterns was significantly 
higher in the monotherapy group (odds ratio= 1.7; confidence interval= 1.401-
2.039; p< 0.0001) as compared to the combination therapy group, while control-
ling for covariates. CONCLUSIONS: Patients on monotherapy were more likely 
to change treatment patterns as compared to those on combination therapy in 
Texas Medicaid. Future research assessing the benefits of combination therapy 
over monotherapy is needed.
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OBJECTIVES: Despite clinical efficacy of anti-inflammatory and immunosuppres-
sive actions in treating systemic lupus erythematous (SLE), numerous adverse 
events (AEs) have been observed in glucocorticoid (GC) use. To date, no national, 
population-based studies have been conducted in Asia to understand the long-
term impact of GC use in SLE patients. The aim of our study is to examine the AEs 
associated with GC use among an ethnic Chinese SLE cohort. METHODS: Our 
study subjects were newly diagnosed SLE patients aged 18 and older who received 
at least 1 prescription of systemic steroid between January 1, 2001 and December 
31, 2012. The earliest prescription date of systemic GC of each subject was defined 
as the index date. For each subject, we calculated average prednisolone-equivalent 
dose and medication possession ratio (MPR) of GC use every 90 days each patient 
after index date. Generalized estimating equations (GEE) adjusted for propensity 
score were applied to examine the association between longitudinal GC use and 
risks of pre-specified AEs (musculoskeletal, gastrointestinal, ophthalmologic, 
infectious, cardiovascular, neuropsychiatric, metabolic, and dermatologic dis-
eases). RESULTS: We identified 11,288 SLE patients from Taiwan’s National Health 
Insurance Research Database (NHIRD) (mean follow-up: 6.28 years). Multivariate 
GEE models showed that higher dose and higher MPR of GC use were associated 
with increased risk of osteonecrosis (adjusted odds ratio (aOR) ranged from 2.87 
to 9.09). Similar results were found regarding the risk of osteoporosis (aOR ranged 
from1.71 to 3.67), bacterial infection (aOR ranged from 2.12 to 3.89), Cushingoid 
syndrome (aOR ranged from 6.51 to 62.03) and sleep disorder (aOR ranged from 
1.42 to 3.59). CONCLUSIONS: Our empirical analysis found that dose and intensity 
of GC use were both associated with higher risks of AEs. To our knowledge, this is 
the first study to document longitudinal use of GC and associated AEs among a 
nationwide Asian SLE cohort.
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OBJECTIVES: The objective of this review was to assess the need for intraoperative 
surgical interventions to prevent bleeding and leaks during the two most common 
procedures for bariatric surgery, laparoscopic sleeve gastrectomy (LSG) and lapa-
roscopic Roux-en-Y gastric bypass (LRYGB). METHODS: A literature search was 
performed using MEDLINE®, EMBASETM, and Biosis from January 2010 through 
November 2014. Titles were searched using key words laparoscopic sleeve gas-
trectomy, sleeve gastrectomy, or gastric bypass and filtered by searching the full 
citation for staple line, laparoscopic, leak or bleed, and intraoperative or inter-
vention with appropriate truncations. Additional references extending to 2008 
were cited by or referenced in manually filtered articles. RESULTS: The search 
yielded 144 titles and abstracts. From these, 11 full articles were reviewed and 6 
were included, along with 11 additional articles identified through citations. For 
LSG, the incidence of intraoperative leaks and bleeds ranged from 1.15-3.93% and 
1.08-4.07%, respectively. For LRYGB, leaks occurred in 3.79-8.26% and bleeds in 
2.25-3.45% of cases. Lack of standardized leak testing methods makes inter-study 
comparisons difficult. Bleeds, considered a nuisance during surgery, are treated 
routinely with sealants or suturing but may be self-limiting and often go unre-
ported. Intraoperative leaks and bleeds are associated with variables in stapler 
efficacy and influenced by inherent characteristics of the tissue as well as the 
experience of the surgeon. The use of staple line buttressing, oversewing, and/or 
tissue sealants appears to be common practice as a precautionary measure but has 
been criticized as unnecessary and having a negative impact on efficiency factors 
such as operative time, cost, or length of stay. CONCLUSIONS: Widespread use of 
precautionary measures and underreporting suggest the incidence of intraopera-
tive leaks and bleeds at the staple line may be underestimated. Improvements in 
stapler design may increase efficiency while reducing the cost of precautionary 
measures and intraoperative interventions.
vs. 27.0%) and antispasmodics (24.7% vs. 15.9%) than those initiating with a non-
oral DMT (all p< 0.001). A higher proportion of non-oral initiators had an MS-related 
inpatient admission (8.8% vs. 5.7%, p< 0.001), were prescribed oral corticoster-
oids (38.2% vs. 33.3%) and had a diagnosis of non-neuropathic pain (52.1% vs. 
47.8%), headache (30.2% vs. 26.3%) and neuropathic pain (18.6% vs. 14.7%) than 
oral initiators (all p< 0.05). CONCLUSIONS: This study showed that despite being 
widely available for only a short period of time relative to injected and infused 
DMTs, oral formulations have captured half the market among treatment-naïve 
MS patients. Channeling could be influenced by age, concomitant medication use 
and co-morbid disease.
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OBJECTIVES: Sleep deprivation and disturbances can result in reduced quality of 
life, lowered productivity and impaired daytime functioning leading to increased 
errors & accidents. Use of sleep aids to treat insomnia is fairly common among 
the general population and analyzing the factors predicting the use of sleep 
medication would help us develop better treatment programs for those affected 
with this problem. To investigate the relationship among age, gender, ethnicity, 
employment status, perceived health status and other aspects related to the use 
of sleep medication in the United States population. METHODS: This was a ret-
rospective, cross-sectional study using data from the 2010 National Ambulatory 
Medical Care Survey (NAMCS), a nationally representative data of US population. 
The study population included all respondents over the age of 18. A multiple logis-
tic regression model was built to analyze odds of reporting use of prescription or 
non-prescription sleep medication. The statistical package SAS version 9.1 [SAS 
institute, Cary, NC.] was used for analysis. RESULTS: Approximately one tenth of 
the population reported the use of sleep medications. The odds of reporting use of 
sleep medication were significantly lower among minority races (OR= 0.549, 95% 
CI= 0.303-0.995) compared with African-American. The odds of sleep medication 
use were significantly higher among age groups of 24-44 years and 44-64 years 
as compared with 18-24 years (OR= 2.133, 95% CI= 1.501-3.030 and OR= 2.888, 95% 
CI= 1.983-4.206, respectively), non-Hispanics (OR= 1.678, 95% CI= 1.178-2.391), 
smokers (OR= 1.243 95% CI= 1.056-1.464), public insured and uninsured compared 
with private insured(OR= 1.338, 95% CI= 1.102-1.625 and OR= 1.326, 95% CI= 1.025-
1.717 respectively), respondents with COPD (OR= 1.320, 95% CI= 1.009-1.729) and 
depression (OR= 4.345, 95%CI= 3.745-5.029). CONCLUSIONS: Differences in sleep 
medication use were seen among specific sub-populations. Further research on 
why such differences exist is necessary. The factors identified in this study should 
be further investigated to identify vulnerable populations to investigate underlying 
causes of sleep disorders.
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OBJECTIVES: Examine time to first DMD prescription in newly diagnosed MS 
patients. METHODS: This retrospective database analysis of newly diagnosed MS 
patients was conducted using a national managed care database. Patients 18–64 
years, with first MS claim (ICD-9-CM: 340.xx) from 1/1/2008–12/31/2011 (index 
date), continuous eligibility for 6 months pre- and 24 months post-index, who had 
≥ 1 DMD claim during the 24-month post-index period were included. Patients who 
had evidence of DMD use prior to first MS claim were excluded. Categorical and 
binary variables were summarized using frequencies and percentages. Continuous 
variables were summarized using means, SDs and medians. RESULTS: Total of 
7993 MS patients met study inclusion criteria. Mean age was 42.7 years (SD= 10.2); 
75.5% were female. Patients were most likely to be from the Midwest (32.6%) or 
Northeast (30.3%) regions, which reflects sampling for the national database used 
in this study. Average time from first MS diagnosis to first DMD claim was 150 days 
(SD= 181), with median time of 64 days. Examining time to first DMD treatment 
showed that 28.2% received their first DMD in < 30 days, 48.1% in < 60 days, 58.7% 
in < 90 days and 71.6% in < 180 days. Over one-quarter of patients (28.4%) did not 
have their first DMD claim for ≥ 180 days following first MS diagnosis. A second-
ary analysis examined time to first DMD claim for newly treated patients with 
any available data in the post-index period (n= 9359). Mean and median times to 
DMD treatment for this broader population were 295.5 (SD= 408.4) and 89 days, 
respectively. CONCLUSIONS: This study demonstrates that many patients with 
newly diagnosed MS have a delay before having their first DMD claim, with 28.4% 
waiting to start therapy for ≥ 6 months. Data suggest early initiation of DMD 
therapy following a diagnosis of relapsing MS is important for optimizing MS 
management.
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OBJECTIVES: Monotherapy with antiepileptic drugs (AEDs) is the preferred initial 
management approach in patients with epilepsy. Differences in treatment patterns 
were assessed across monotherapy and combination therapy users. METHODS: 
Texas Medicaid medical and prescription claims from January 1, 2007 - October 
31, 2010 were extracted for adults (18-63 years) diagnosed with epilepsy. The index 
date was the first date of AED use with no previous use in the 6-month pre-index 
period. Patients were followed for 12 months. Combination therapy was defined 
